Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-1.83 Insider Own0.70% Shs Outstand151.56M Perf Week-5.14%
Market Cap7.13B Forward P/E123.12 EPS next Y0.38 Insider Trans-13.50% Shs Float150.30M Perf Month7.45%
Income-275.00M PEG- EPS next Q-0.03 Inst Own97.40% Short Float3.24% Perf Quarter3.32%
Sales667.70M P/S10.68 EPS this Y-635.70% Inst Trans-1.09% Short Ratio5.97 Perf Half Y29.38%
Book/sh8.22 P/B5.72 EPS next Y416.70% ROA-15.00% Target Price51.36 Perf Year-20.97%
Cash/sh4.33 P/C10.87 EPS next 5Y- ROE-21.20% 52W Range27.14 - 80.71 Perf YTD-40.75%
Dividend- P/FCF- EPS past 5Y-26.20% ROI-13.70% 52W High-41.73% Beta2.05
Dividend %- Quick Ratio3.70 Sales past 5Y27.50% Gross Margin80.50% 52W Low73.29% ATR1.59
Employees1500 Current Ratio3.90 Sales Q/Q28.90% Oper. Margin-40.20% RSI (14)45.09 Volatility3.49% 3.34%
OptionableYes Debt/Eq0.28 EPS Q/Q-0.70% Profit Margin-41.20% Rel Volume0.84 Prev Close46.71
ShortableYes LT Debt/Eq0.23 EarningsOct 27 BMO Payout- Avg Volume815.65K Price47.03
Recom2.40 SMA20-2.20% SMA50-1.10% SMA2004.75% Volume682,371 Change0.69%
Jan-21-16Reiterated Leerink Partners Outperform $84 → $58
Jan-21-16Downgrade Morgan Stanley Overweight → Underweight
Jan-21-16Downgrade JP Morgan Overweight → Neutral
Oct-07-15Reiterated Barclays Overweight $77 → $79
Sep-01-15Upgrade Morgan Stanley Underweight → Overweight
Jun-09-15Initiated Guggenheim Neutral
May-21-15Initiated Barclays Overweight $74
Jan-08-15Reiterated Mizuho Buy $72 → $81
Jul-31-14Reiterated Mizuho Buy $61 → $59
Apr-10-14Upgrade Mizuho Neutral → Buy $55 → $61
Apr-09-14Reiterated MKM Partners Sell $32 → $35
Feb-28-14Reiterated UBS Neutral $42 → $53
Feb-28-14Reiterated MKM Partners Sell $26 → $32
Feb-28-14Reiterated Mizuho Neutral $33 → $56
Dec-05-13Downgrade UBS Buy → Neutral $37 → $42
Nov-01-13Reiterated Mizuho Neutral $30 → $33
Oct-30-13Initiated FBR Capital Mkt Perform $31
May-24-13Reiterated UBS Buy $32 → $37
May-24-13Downgrade MKM Partners Neutral → Sell
Apr-18-13Downgrade Mizuho Buy → Neutral $30 → $26
Sep-30-16 08:30AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : September 30, 2016
Sep-27-16 10:39AM  Jim Cramer -- Gilead Needs to Make an Acquisition
09:54AM  Cramer's Stop Trading: GILD, GWPH & ALKS
Sep-23-16 04:33PM  Virgin Extends Drop As Alaska Air Merger Review Grows Longer
Sep-20-16 04:14PM  ALKERMES PLC. Files SEC form 8-K/A, Change in Directors or Principal Officers
Sep-19-16 04:00PM  Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Business Wire
Sep-15-16 11:13AM  Moving Average Crossover Alert: Alkermes (ALKS)
Sep-12-16 07:00AM  Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and Substance Use Disorders Business Wire +5.20%
Sep-09-16 01:51PM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : September 9, 2016
Sep-08-16 08:03AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : September 8, 2016
Sep-06-16 04:00PM  Alkermes Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Business Wire
Aug-25-16 10:00AM  ETFs with exposure to Alkermes Plc : August 25, 2016
Aug-24-16 08:03AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : August 24, 2016
Aug-15-16 10:00AM  Want a Dash for Trash? Why Not Look at Alkermes
Aug-11-16 08:14AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : August 11, 2016
Aug-08-16 07:00AM  Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia Business Wire
Aug-04-16 02:36PM  ETFs with exposure to Alkermes Plc : August 4, 2016
Aug-03-16 01:04PM  ALKERMES PLC. Financials
12:29PM  Alkermes Plc :ALKS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016
Jul-29-16 12:44PM  ALKERMES PLC. Files SEC form 8-K, Other Events
11:06AM  Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook
Jul-28-16 08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today -7.05%
08:20AM  Alkermes reports 2Q loss
07:07AM  Q2 2016 Alkermes Plc Earnings Release - Before Market Open
07:06AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:00AM  Alkermes plc Reports Second Quarter 2016 Financial Results Business Wire
Jul-27-16 03:00PM  A Look At Recro Pharma Inc (REPH) and Alkermes Plc (ALKS)s Topline Triumph at Insider Monkey
06:00AM  Jim Cramer's Top Takeaways: Acacia Communications, KeyCorp, Alkermes
Jul-26-16 07:09PM  Cramer Remix: It's time for Jack Dorsey to make a choice at CNBC
03:00PM  [$$] Three Biotech Q2 Reports Hold Potential at Barrons.com
Jul-22-16 07:53PM  Whats Been Beating down the Fidelity Growth Company Fund in 2016?
Jul-21-16 04:00PM  Alkermes to Host Conference Call to Discuss Second Quarter 2016 Financial Results Business Wire
Jun-21-16 11:21AM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : June 21, 2016
Jun-20-16 08:38AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 20, 2016
Jun-08-16 04:19PM  ALKERMES PLC. Files SEC form 8-K, Other Events
02:10PM  ETFs with exposure to Alkermes Plc : June 8, 2016
Jun-02-16 04:11PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers
Jun-01-16 04:06PM  Alkermes Rises on Evercores Buy Rating, Buying Support
04:00PM  Alkermes Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare Conference Business Wire
08:30AM  Alkermes Plc Conference Call to Discuss Data and Study Design from FORWARD-3 and FORWARD-4 Studies of ALKS 5461 scheduled for 8:30 am ET today
May-26-16 04:50PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur
11:30AM  Alkermes Begins Phase I Study on Immuno-Oncology Drug
07:00AM  Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors Business Wire
May-25-16 11:47AM  Alkermes Initiates Phase 1 Clinical Trial Of Immuno-Oncology Drug Candidate ALKS 4230
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 Business Wire
May-24-16 02:45PM  ETFs with exposure to Alkermes Plc : May 24, 2016
07:00AM  Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting Business Wire
May-04-16 07:23AM  FDA Warns of Rare Impulse Reactions to Abilify Medication at The Wall Street Journal
May-03-16 10:38PM  FDA Warns of Rare Reactions to Abilify Medication at The Wall Street Journal
10:52AM  Alkermes Plc :ALKS-US: Earnings Analysis: Q1, 2016 By the Numbers
Apr-29-16 09:31AM  Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss
Apr-28-16 02:59PM  Edited Transcript of ALKS earnings conference call or presentation 28-Apr-16 12:30pm GMT
09:34AM  Alkermes reports 1Q loss
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN
07:07AM  Q1 2016 Alkermes Plc Earnings Release - Before Market Open CCBN
07:06AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:00AM  Alkermes plc Reports First Quarter 2016 Financial Results Business Wire
06:58AM  Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1 Results Business Wire
Apr-21-16 04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Business Wire
Apr-14-16 11:43AM  Stalking a Speculative Trade in Alkermes
Apr-01-16 08:09AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : April 1, 2016
Mar-31-16 07:00AM  Study on Extended-Release Naltrexone in Opioid-Dependent Patients Involved in Criminal Justice System Published in the New England Journal of Medicine Business Wire +6.15%
Mar-28-16 07:08AM  Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research Society Conference at noodls
07:00AM  Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research Society Conference Business Wire
Mar-22-16 01:05AM  XBI News as of March 16: Mid-Caps Under Pressure +5.99%
Mar-09-16 04:00PM  Alkermes Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Business Wire
Mar-03-16 02:17PM  Hedge Funds Regret Buying These Stocks in Q4 at Insider Monkey -6.48%
09:21AM  Why Alkermes (ALKS) Stock Might be a Great Pick
Mar-01-16 04:00PM  Alkermes Corporate Presentation to be Webcast at the Cowen and Company 36th Annual Health Care Conference Business Wire +6.63%
Feb-26-16 04:05PM  Alkermes Q4 Loss Narrower than Expected, Updates Pipeline
Feb-25-16 01:59PM  Edited Transcript of ALKS earnings conference call or presentation 25-Feb-16 1:30pm GMT
11:36AM  Alkermes reports 4Q loss
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today
07:07AM  Q4 2015 Alkermes Plc Earnings Release - Before Market Open
07:06AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:01AM  Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and Provides Financial Expectations for 2016 Business Wire
07:00AM  Alkermes Announces Positive Topline Results From Clinical Study of Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia Business Wire
Feb-18-16 04:00PM  Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results Business Wire -5.85%
Feb-12-16 06:04AM  5 Breakout Stocks to Trade for Big Gains at TheStreet
Feb-11-16 02:15PM  Alkermes' ALKS 3831 in 2nd Phase III Study for Schizophrenia
Feb-10-16 08:30AM  Who Will Come Out On Top As Flu Season Draws Down Accesswire
07:00AM  Alkermes Announces Initiation of Second Phase 3 Study of ALKS 3831 for Schizophrenia Business Wire
Feb-09-16 08:36AM  Alkermes CEO Richard Pops Isn't Giving Up On Breakthrough Depression Drugs at Forbes
Feb-04-16 08:59AM  Why Did Biotech Fall Off a Cliff in January? at Motley Fool
Feb-02-16 04:00PM  Alkermes Corporate Presentation to be Webcast at Two Upcoming Conferences Business Wire
Jan-28-16 03:29PM  Alkermes short bets built up ahead of depression drug setback -5.34%
Jan-27-16 03:25PM  Alkermes Initiates Early-Stage Study on Alzheimer's Drug -6.88%
Jan-25-16 07:07AM  Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 at noodls
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Business Wire
Jan-24-16 02:00PM  8 Things That Could Lift Biotech Stocks Out of Bear Market at TheStreet
Jan-23-16 10:15AM  4 Stocks That Punished Shareholders Last Week at 24/7 Wall St.
Jan-22-16 03:10PM  Alkermes Hit 52-Week Low on Unfavorable Phase III Data +7.33%
01:11PM  Alkermes Learns Makeovers Aren't Easy at Bloomberg
Jan-21-16 09:42PM  [$$] Business Watch at The Wall Street Journal -44.24%
06:21PM  Why Alkermes, Scholastic, and MGIC Investment Slumped Today at Motley Fool
01:40PM  Why These 5 Stocks Are Plummeting Today at Insider Monkey
01:13PM  [$$] Alkermes Depression Drug Disappoints at The Wall Street Journal
01:05PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of Alkermes plc Business Wire
01:02PM  Alkermes Hits Two-Year Low On Depression Drug Failure at Investor's Business Daily
12:19PM  Alkermes downgraded by Morgan Stanley and JP Morgan
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; INVEGA TRINZA for the treatment of schizophrenia used in people who have been treated with INVEGA SUSTENNA; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to improve walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in a Phase III study for the treatment of major depressive disorder; ALKS 3831, which is in a Phase II study to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in a Phase I study to treat multiple sclerosis; ALKS 6428, which is in a phase III study to help physicians transition patients from physical dependence on opioids to antagonist therapy; Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I study for the treatment of schizophrenia; ALKS 7119 that is in a Phase I study for the treatment of various central nervous system diseases; RDB 1450, a proprietary investigational biologic cancer immunotherapy product that is in pre-clinical stage. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Janssen Pharmaceutica N.V.; AstraZeneca plc; and Acorda Therapeutics, Inc. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 22Option Exercise18.113,83469,41549,145Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 22Sale50.843,834194,92645,311Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 21Option Exercise18.111,16621,11046,477Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 21Sale50.811,16659,24245,311Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 16Option Exercise18.115,00090,52550,311Sep 19 05:21 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 16Sale48.875,000244,33145,311Sep 19 05:21 PM
MITCHELL PAUL JDirectorSep 06Option Exercise18.292,00036,58010,000Sep 07 05:13 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Sep 06Option Exercise14.382,38234,25322,816Sep 07 05:16 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 06Option Exercise18.1110,000181,05055,311Sep 07 05:31 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 06Sale46.0210,000460,23545,311Sep 07 05:31 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Sep 06Sale45.9229,9761,376,62722,227Sep 07 05:27 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Sep 06Sale45.922,382109,37820,434Sep 07 05:16 PM
MITCHELL PAUL JDirectorSep 06Sale45.922,00091,8348,000Sep 07 05:13 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Aug 05Option Exercise16.556,04299,99517,803Aug 08 05:09 PM
MITCHELL PAUL JDirectorAug 04Option Exercise18.292,00036,58010,000Aug 05 05:04 PM
MITCHELL PAUL JDirectorAug 04Sale49.482,00098,9668,000Aug 05 05:04 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 27Option Exercise16.5534,399569,30379,710Jul 28 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 27Sale51.9534,3991,787,07645,311Jul 28 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 26Option Exercise16.5580013,24046,111Jul 28 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 26Sale51.8280041,45545,311Jul 28 05:06 PM
MITCHELL PAUL JDirectorJul 05Option Exercise18.292,00036,58010,000Jul 06 05:17 PM
MITCHELL PAUL JDirectorJul 05Sale45.812,00091,6208,000Jul 06 05:17 PM
MITCHELL PAUL JDirectorJun 06Option Exercise18.292,00036,58010,000Jun 07 05:33 PM
MITCHELL PAUL JDirectorJun 06Sale44.982,00089,9508,000Jun 07 05:33 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 28Option Exercise0.001,250020,840Jun 01 06:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 28Option Exercise0.0013,7500598,372Jun 01 06:06 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 28Option Exercise0.002,5000153,012Jun 01 05:52 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMay 28Option Exercise0.002,500057,778Jun 01 05:35 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 28Option Exercise0.003,750047,076Jun 01 05:26 PM
Cooke ShanePresident, Alkermes plcMay 28Option Exercise0.005,750063,334Jun 01 05:23 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 28Option Exercise0.001,750052,771Jun 01 05:15 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMay 28Option Exercise0.003,750038,305Jun 01 05:09 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMay 28Option Exercise0.002,500026,650Jun 01 06:34 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.May 21Option Exercise0.004,125011,074May 23 06:17 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMay 21Option Exercise0.003,750056,537May 23 05:59 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 21Option Exercise0.004,500045,444May 23 05:46 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncMay 21Option Exercise0.002,125051,711May 23 05:37 PM
BIBERSTEIN KATHRYN LEVP/CLO/CCO Alks Inc; Sec ALKSMay 21Option Exercise0.004,500036,076May 23 05:30 PM
MITCHELL PAUL JDirectorMay 04Option Exercise18.292,00036,58010,000May 05 05:27 PM
MITCHELL PAUL JDirectorMay 04Sale38.602,00077,2008,000May 05 05:27 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncApr 22Option Exercise20.793,13265,11449,586Apr 25 05:26 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Apr 20Option Exercise20.7916,875350,831163,637Apr 20 05:19 PM
BIBERSTEIN KATHRYN LEVP/CLO/CCO Alks Inc; Sec ALKSApr 20Option Exercise20.7912,657263,13931,576Apr 20 05:34 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Apr 20Sale41.0916,875693,403146,762Apr 20 05:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 19Option Exercise20.7918,750389,813595,247Apr 20 05:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 19Sale40.1518,750752,863576,497Apr 20 05:16 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncApr 18Option Exercise20.795,368111,60151,822Apr 20 05:03 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncApr 18Sale39.275,368210,81646,454Apr 20 05:03 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 12Option Exercise20.7925,000519,750601,497Apr 13 05:15 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 12Sale37.7925,000944,839576,497Apr 13 05:15 PM
MITCHELL PAUL JDirectorApr 04Option Exercise18.292,00036,58010,000Apr 05 05:23 PM
MITCHELL PAUL JDirectorApr 04Sale35.652,00071,3008,000Apr 05 05:23 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 22Option Exercise20.7925,000519,750601,497Mar 23 05:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 22Sale31.7725,000794,353576,497Mar 23 05:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 15Option Exercise20.7925,000519,750601,497Mar 16 05:35 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 15Sale31.4025,000784,910576,497Mar 16 05:35 PM
MITCHELL PAUL JDirectorMar 04Option Exercise18.292,00036,58010,000Mar 04 05:38 PM
MITCHELL PAUL JDirectorMar 04Sale32.802,00065,6008,000Mar 04 05:38 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 03Option Exercise18.5526,128484,71952,787Mar 04 05:27 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 03Option Exercise0.002,8130146,762Mar 04 05:28 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncMar 03Option Exercise0.001,250046,860Mar 04 05:15 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Mar 03Option Exercise0.003,25008,004Mar 04 05:33 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 03Option Exercise0.0013,0000576,497Mar 04 05:29 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 03Option Exercise0.002,813024,150Mar 04 05:35 PM
ANSTICE DAVID WDirectorMar 03Buy32.875,000164,36615,000Mar 04 05:36 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000563,497Mar 01 05:45 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Feb 26Option Exercise0.003,750039,628Mar 01 05:31 PM
Cooke ShanePresident, Alkermes plcFeb 26Option Exercise0.004,425054,665Mar 01 05:23 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncFeb 26Option Exercise0.001,100045,967Mar 01 05:20 PM
BIBERSTEIN KATHRYN LEVP/CLO/CCO Alks Inc; Sec ALKSFeb 26Option Exercise0.003,75005,129Mar 01 05:13 PM
BLOOM FLOYD EDirectorFeb 08Option Exercise18.2920,000365,800128,881Feb 10 05:17 PM
MITCHELL PAUL JDirectorFeb 04Option Exercise18.292,00036,58010,000Feb 04 05:13 PM
MITCHELL PAUL JDirectorFeb 04Sale32.812,00065,6208,000Feb 04 05:13 PM
MITCHELL PAUL JDirectorJan 04Option Exercise18.292,00036,58010,000Jan 04 06:46 PM
MITCHELL PAUL JDirectorJan 04Sale77.332,000154,6608,000Jan 04 06:46 PM
BREYER ROBERT ADirectorJan 04Sale77.332,000154,66035,156Jan 04 06:44 PM
Stejbach MarkChief Commercial OfficerDec 28Option Exercise17.3010,000173,00029,564Dec 28 05:05 PM
Stejbach MarkChief Commercial OfficerDec 28Sale80.2410,000802,39219,564Dec 28 05:05 PM
Cooke ShanePresident, Alkermes plcDec 23Option Exercise14.6018,000262,80068,240Dec 23 05:22 PM
Cooke ShanePresident, Alkermes plcDec 23Sale77.2318,0001,390,09650,240Dec 23 05:22 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 07Option Exercise18.6037,500697,500590,997Dec 08 05:37 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 07Sale72.0637,5002,702,433553,497Dec 08 05:37 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Dec 01Option Exercise18.6010,000186,000151,324Dec 02 06:12 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 01Option Exercise18.6050,000930,000603,497Dec 02 06:17 PM
Stejbach MarkChief Commercial OfficerDec 01Option Exercise17.3018,000311,40037,564Dec 02 06:20 PM
Stejbach MarkChief Commercial OfficerDec 01Sale72.1818,0001,299,20919,564Dec 02 06:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcDec 01Sale72.2950,0003,614,344553,497Dec 02 06:17 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Dec 01Sale72.1810,000721,768141,324Dec 02 06:12 PM
BREYER ROBERT ADirectorDec 01Sale73.462,000146,92037,156Dec 02 06:00 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 24Option Exercise18.115,52399,99455,380Nov 24 05:44 PM
Cooke ShanePresident, Alkermes plcNov 23Option Exercise14.6018,000262,80068,240Nov 24 05:16 PM
Cooke ShanePresident, Alkermes plcNov 23Sale72.6218,0001,307,09550,240Nov 24 05:16 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 10Option Exercise15.9510,000159,50059,857Nov 12 05:18 PM
FRATES JAMES MSVP & CFO, Alkermes plcNov 10Sale72.3410,000723,39549,857Nov 12 05:18 PM
Brown Iain MichaelVP, Finance & CAONov 04Option Exercise18.606,178114,91144,867Nov 04 05:45 PM
Stejbach MarkChief Commercial OfficerNov 02Option Exercise17.3018,000311,40037,964Nov 04 05:36 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Nov 02Option Exercise20.792,68755,86336,633Nov 04 05:41 PM
BREYER ROBERT ADirectorNov 02Sale71.802,000143,60039,156Nov 04 05:39 PM
Stejbach MarkChief Commercial OfficerNov 02Sale72.0618,0001,297,16819,964Nov 04 05:36 PM
Brown Iain MichaelVP, Finance & CAOOct 29Option Exercise18.6010,822201,28949,511Oct 30 05:27 PM